News
Oculis Announce a $100 Million Capital Increase
Swiss-Icelandic ophthalmic laboratory Oculis announced a $100 million capital increase on Friday. The financial operation was carried out through an oversubscribed offering of 5 million shares at $20 each. Born in 2017 in Iceland, the company then expanded to the EPFL Innovation Park before setting up its headquarters in Zug. It has offices…
Read MoreWyss Center licenses Epios® to BrainScape Medical
The Wyss Center for Bio and Neuro Engineering announced a strategic partnership with BrainScape Medical, a newly formed company specializing in long-term brain monitoring and neurostimulation. This collaboration marks a major step forward in translating innovative neurotechnologies into real clinical solutions. The Wyss Center in Geneva has granted BrainScape Medical an exclusive license for…
Read MoreLaunch of the Deep Tech Nation Information Platform
The Deep Tech Nation Switzerland Foundation (DTN) and the Startupticker Foundation have launched the Deep Tech Nation Information Platform to help venture capitalists (VCs) and institutional investors navigate Switzerland’s deep tech ecosystem. The platform enhances access to information, promotes investment in Swiss deep tech start-ups, and aims to strengthen Switzerland’s position as a…
Read MoreBiped Robotics Supported By FIT With a Digital Growth Loan
Biped Robotics develops NOA, a harness to improve mobility for visually impaired people. The number of people with impaired vision is rising steadily, and now stands at 300 million worldwide, including 6 million blind people. For them, getting around independently is a daily challenge. Biped Robotics’ solution to this is NOA, a shoulder-worn harness…
Read MoreLemna Bio awarded a CHF 100’000 EPFL Innogrant
Lemna Bio – an EPFL startup hosted by Professor Dal Pararo’s Laboratory of Biomolecular Modeling – has been awarded a CHF 100,000 Innogrant by the jury at the EPFL Startup Launchpad. With ageing populations and chronic diseases on the rise, the demand for effective medicines and therapies has never been greater. Yet, for decades, drug development has…
Read MoreEBAMed raised EUR 1.6 Million
The Geneva-based company has just secured a further EUR 1.6 Million from CDP Venture Capital and the European Union. This brings the total amount raised in the series A financing round to EUR 16 Million. EBAMed, is a Geneva-Based start-up developing a guidance system for the non-invasive treatment of heart arrhythmias through Proton Therapy.…
Read MoreComphya Receives FDA IDE Approval to Initiate U.S. Clinical Trial for CaverSTIM
Comphya SA, a pioneering medical technology company based in canton of Vaud and the developer of CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a clinical trial to evaluate CaverSTIM in the United States. …
Read More5 life sciences projects from CHUV, EPFL and HEIG-VD awarded by FIT
Five projects have received support from the Foundation for Innovation and Technology (FIT) in the form of Tech Grants: Bio-CapnoMAD from CHUV, Helix Robotics, MyJoint and Neurovia from EPFL, and Grenat from HEIG-VD will be able to continue developing their technologies with the backing of the Foundation. Bio-CapnoMAD provides innovative solutions to fight sleep…
Read MoreHelix Robotics receives CHF 150,000 from Venture Kick
Helix Robotics is developing the first commercial soft robot manipulator. By combining the safety of soft robotics with industrial precision, the EPFL spin-off aims to enhance automation in food handling and lab automation. The startup was financed with CHF 150,000 by Venture Kick, winning the third stage of the programme. Traditional robotic arms…
Read MoreGARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae. Multidrug-resistant strains of N. gonorrhoeae have emerged globally, limiting treatment options and elevating this pathogen to…
Read More